featured
Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell ALL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial
J. Clin. Oncol 2021 Jan 08;[EPub Ahead of Print], S Kadauke, RM Myers, Y Li, R Aplenc, D Baniewicz, DM Barrett, A Barz Leahy, C Callahan, JG Dolan, JC Fitzgerald, W Gladney, SF Lacey, H Liu, SL Maude, R McGuire, LS Motley, DT Teachey, GB Wertheim, L Wray, AM DiNofia, SA GruppFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.